Brian Higgins

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Gideon Bollag, Peter Hirth, James Tsai et al. · Nature · 2010 · 1.8K citations

Skin Cancer, Medicine, Melanoma +7

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy

Christian Tovar, James Rosinski, Zoran Filipovic et al. · Proceedings of the National Academy of Sciences · 2006 · 699 citations · Full text

Chemoprevention Strategy, Apoptosis, Cell Death +17

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Qingjie Ding, Zhuming Zhang, Jinjun Liu et al. · Journal of Medicinal Chemistry · 2013 · 583 citations · Full text

Drug Target, Chemical Biology, Cancer Biology +19

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Hong Yang, Brian Higgins, Kenneth Kolinsky et al. · Cancer Research · 2010 · 400 citations

Melanoma Cell Lines, Phase Ii, Medicine +15

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Hong Yang, Brian Higgins, Kenneth Kolinsky et al. · Cancer Research · 2011 · 214 citations · Full text

Antitumor Activity, Cancer Biology, Tumor Biology +17